Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001714899-21-000078
Filing Date
2021-08-04
Accepted
2021-08-04 16:07:49
Documents
63
Period of Report
2021-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q dnli-20210630.htm   iXBRL 10-Q 1943664
2 EX-10.1 denalif-starsideletter.htm EX-10.1 41685
3 EX-31.1 exhibit311q22021.htm EX-31.1 9996
4 EX-31.2 exhibit312q22021.htm EX-31.2 9994
5 EX-32.1 exhibit321q22021.htm EX-32.1 5654
6 EX-32.2 exhibit322q22021.htm EX-32.2 5761
  Complete submission text file 0001714899-21-000078.txt   7545793

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20210630.xsd EX-101.SCH 50612
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT dnli-20210630_cal.xml EX-101.CAL 56465
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT dnli-20210630_def.xml EX-101.DEF 232340
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20210630_lab.xml EX-101.LAB 590397
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20210630_pre.xml EX-101.PRE 384677
12 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20210630_htm.xml XML 1226056
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38311 | Film No.: 211144038
SIC: 2836 Biological Products, (No Diagnostic Substances)